| Name | 4-[[2-(4-nitro-1,2-dihydropyrazol-3-ylidene)benzimidazol-5-yl]methyl]morpholine |
|---|
| Molecular Formula | C15H16N6O3 |
|---|---|
| Molecular Weight | 328.32600 |
| Exact Mass | 328.12800 |
| PSA | 115.65000 |
| LogP | 2.15450 |
|
~59%
825619-29-2 |
| Literature: ASTEX THERAPEUTICS LIMITED Patent: WO2007/77435 A1, 2007 ; Location in patent: Page/Page column 205 ; WO 2007/077435 A1 |
|
~%
825619-29-2 |
| Literature: Zheng, Youguang; Zheng, Ming; Ling, Xin; Liu, Yi; Xue, Yunsheng; An, Lin; Gu, Ning; Jin, Min Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 12 p. 3523 - 3530 |
|
~%
825619-29-2 |
| Literature: Zheng, Youguang; Zheng, Ming; Ling, Xin; Liu, Yi; Xue, Yunsheng; An, Lin; Gu, Ning; Jin, Min Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 12 p. 3523 - 3530 |
|
~%
825619-29-2 |
| Literature: Zheng, Youguang; Zheng, Ming; Ling, Xin; Liu, Yi; Xue, Yunsheng; An, Lin; Gu, Ning; Jin, Min Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 12 p. 3523 - 3530 |
|
~%
825619-29-2 |
| Literature: Zheng, Youguang; Zheng, Ming; Ling, Xin; Liu, Yi; Xue, Yunsheng; An, Lin; Gu, Ning; Jin, Min Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 12 p. 3523 - 3530 |